AAAAAA

   
Results: 1-21 |
Results: 21
CHOLESTEROL REDUCTION AND CLINICAL BENEFIT - ARE THERE LIMITS TO OUR EXPECTATIONS
Authors: FAGER G WIKLUND O
Citation: G. Fager et O. Wiklund, CHOLESTEROL REDUCTION AND CLINICAL BENEFIT - ARE THERE LIMITS TO OUR EXPECTATIONS, Arteriosclerosis, thrombosis, and vascular biology, 17(12), 1997, pp. 3527-3533
QUANTITATION OF PLATELET-DERIVED GROWTH-FACTOR RECEPTORS IN HUMAN ARTERIAL SMOOTH-MUSCLE CELLS IN-VITRO
Authors: KRETTEK A FAGER G JERNBERG P OSTERGRENLUNDEN G LUSTIG F
Citation: A. Krettek et al., QUANTITATION OF PLATELET-DERIVED GROWTH-FACTOR RECEPTORS IN HUMAN ARTERIAL SMOOTH-MUSCLE CELLS IN-VITRO, Arteriosclerosis, thrombosis, and vascular biology, 17(11), 1997, pp. 2395-2404
EFFECT OF PHENOTYPE ON THE TRANSCRIPTION OF THE GENES FOR PLATELET-DERIVED GROWTH-FACTOR (PDGF) ISOFORMS IN HUMAN SMOOTH-MUSCLE CELLS, MONOCYTE-DERIVED MACROPHAGES, AND ENDOTHELIAL-CELLS IN-VITRO
Authors: KRETTEK A FAGER G LINDMARK H SIMONSON C LUSTIG F
Citation: A. Krettek et al., EFFECT OF PHENOTYPE ON THE TRANSCRIPTION OF THE GENES FOR PLATELET-DERIVED GROWTH-FACTOR (PDGF) ISOFORMS IN HUMAN SMOOTH-MUSCLE CELLS, MONOCYTE-DERIVED MACROPHAGES, AND ENDOTHELIAL-CELLS IN-VITRO, Arteriosclerosis, thrombosis, and vascular biology, 17(11), 1997, pp. 2897-2903
PHARMACODYNAMICS AND PHARMACOKINETICS OF THE HMG-COA REDUCTASE INHIBITORS - SIMILARITIES AND DIFFERENCES
Authors: LENNERNAS H FAGER G
Citation: H. Lennernas et G. Fager, PHARMACODYNAMICS AND PHARMACOKINETICS OF THE HMG-COA REDUCTASE INHIBITORS - SIMILARITIES AND DIFFERENCES, Clinical pharmacokinetics, 32(5), 1997, pp. 403-425
CHARACTERIZATION OF HEPARIN AND HEPARAN-SULFATE DOMAINS BINDING TO THE LONG SPLICE VARIANT OF PLATELET-DERIVED GROWTH-FACTOR-A CHAIN
Authors: FEYZI E LUSTIG F FAGER G SPILLMANN D LINDAHL U SALMIVIRTA M
Citation: E. Feyzi et al., CHARACTERIZATION OF HEPARIN AND HEPARAN-SULFATE DOMAINS BINDING TO THE LONG SPLICE VARIANT OF PLATELET-DERIVED GROWTH-FACTOR-A CHAIN, The Journal of biological chemistry, 272(9), 1997, pp. 5518-5524
CORONARY HEART-DISEASE PREVENTION - HOW MUCH CAN WE EXPECT FROM CHOLESTEROL-LOWERING THERAPY
Authors: FAGER G
Citation: G. Fager, CORONARY HEART-DISEASE PREVENTION - HOW MUCH CAN WE EXPECT FROM CHOLESTEROL-LOWERING THERAPY, Atherosclerosis, 134(1-2), 1997, pp. 47-47
A COMPARISON OF CLINICAL AND PHARMACOECONOMIC PROPERTIES OF FLUVASTATIN AND SIMVASTATIN IN THE MANAGEMENT OF PRIMARY HYPERCHOLESTEROLEMIA
Authors: LEVIN LA SCHMIDT A SCHULTE KL BEIL S FAGER G
Citation: La. Levin et al., A COMPARISON OF CLINICAL AND PHARMACOECONOMIC PROPERTIES OF FLUVASTATIN AND SIMVASTATIN IN THE MANAGEMENT OF PRIMARY HYPERCHOLESTEROLEMIA, Atherosclerosis, 134(1-2), 1997, pp. 52-52
PDGF AND ARTERIAL SMOOTH-MUSCLE HYPERPLASIA - POSSIBLE MODULATION BY THROMBIN
Authors: FAGER G
Citation: G. Fager, PDGF AND ARTERIAL SMOOTH-MUSCLE HYPERPLASIA - POSSIBLE MODULATION BY THROMBIN, Atherosclerosis, 134(1-2), 1997, pp. 107-107
EFFECTS OF ERYTHROMYCIN ON PLASMA FLUVASTATIN LEVELS - A PHARMACOKINETIC STUDY
Authors: ABERG J ERIKSSON U FAGER G
Citation: J. Aberg et al., EFFECTS OF ERYTHROMYCIN ON PLASMA FLUVASTATIN LEVELS - A PHARMACOKINETIC STUDY, Atherosclerosis, 134(1-2), 1997, pp. 118-119
DIFFERENTIAL BINDING-PROPERTIES OF PLATELET-DERIVED GROWTH-FACTOR ISOFORMS TO GLYCOSAMINOGLYCANS
Authors: LUSTIG F HOEBEKE J SIMONSON C OSTERGRENLUNDEN G FAGER G
Citation: F. Lustig et al., DIFFERENTIAL BINDING-PROPERTIES OF PLATELET-DERIVED GROWTH-FACTOR ISOFORMS TO GLYCOSAMINOGLYCANS, Atherosclerosis, 134(1-2), 1997, pp. 275-275
EFFECT OF PHENOTYPE ON THE EXPRESSION OF PDGF ISOFORMS IN HUMAN SMOOTH-MUSCLE CELLS, MACROPHAGES, AND ENDOTHELIAL-CELLS IN-VITRO
Authors: KRETTEK A LINDMARK H SIMONSON C FAGER G LUSTIG F
Citation: A. Krettek et al., EFFECT OF PHENOTYPE ON THE EXPRESSION OF PDGF ISOFORMS IN HUMAN SMOOTH-MUSCLE CELLS, MACROPHAGES, AND ENDOTHELIAL-CELLS IN-VITRO, Atherosclerosis, 134(1-2), 1997, pp. 275-275
EXPRESSION OF SHORT AND LONG PLATELET-DERIVED GROWTH FACTORS-B (PDGF-B) HOMODIMERS AND THEIR BINDING TO HEPARIN
Authors: SIMONSON C LUSTIG F HOEBEKE J VELGEROUSSEL F OSTERGRENLUNDEN G FAGER G
Citation: C. Simonson et al., EXPRESSION OF SHORT AND LONG PLATELET-DERIVED GROWTH FACTORS-B (PDGF-B) HOMODIMERS AND THEIR BINDING TO HEPARIN, Atherosclerosis, 134(1-2), 1997, pp. 276-276
AUTOMATED ENHANCED CHEMILUMINESCENCE TECHNIQUE IN EVALUATING TOTAL ANTIOXIDATIVE CAPACITY IN HUMAN SERUM
Authors: HALLBERG IH FAGER G LUNDH A WIKLUND O
Citation: Ih. Hallberg et al., AUTOMATED ENHANCED CHEMILUMINESCENCE TECHNIQUE IN EVALUATING TOTAL ANTIOXIDATIVE CAPACITY IN HUMAN SERUM, Atherosclerosis, 130, 1997, pp. 43-43
N-ACETYLCYSTEINE TREATMENT LOWERS PLASMA HOMOCYSTEINE BUT NOT SERUM LIPOPROTEIN(A) LEVELS
Authors: WIKLUND O FAGER G ANDERSSON A LUNDSTAM U MASSON P HULTBERG B
Citation: O. Wiklund et al., N-ACETYLCYSTEINE TREATMENT LOWERS PLASMA HOMOCYSTEINE BUT NOT SERUM LIPOPROTEIN(A) LEVELS, Atherosclerosis, 119(1), 1996, pp. 99-106
ALTERNATIVE SPLICING DETERMINES THE BINDING OF PLATELET-DERIVED GROWTH-FACTOR (PDGF-AA) TO GLYCOSAMINOGLYCANS
Authors: LUSTIG F HOEBEKE J OSTERGRENLUNDEN G VELGEROUSSEL F BONDJERS G OLSSON U RUETSCHI U FAGER G
Citation: F. Lustig et al., ALTERNATIVE SPLICING DETERMINES THE BINDING OF PLATELET-DERIVED GROWTH-FACTOR (PDGF-AA) TO GLYCOSAMINOGLYCANS, Biochemistry, 35(37), 1996, pp. 12077-12085
INTERFERON-GAMMA BINDS TO EXTRACELLULAR-MATRIX CHONDROITIN-SULFATE PROTEOGLYCANS, THUS ENHANCING ITS CELLULAR-RESPONSE
Authors: CAMEJO EH ROSENGREN B CAMEJO G SARTIPY P FAGER G BONDJERS G
Citation: Eh. Camejo et al., INTERFERON-GAMMA BINDS TO EXTRACELLULAR-MATRIX CHONDROITIN-SULFATE PROTEOGLYCANS, THUS ENHANCING ITS CELLULAR-RESPONSE, Arteriosclerosis, thrombosis, and vascular biology, 15(9), 1995, pp. 1456-1465
FIRST ANNUAL COPENHAGEN ATHEROSCLEROSIS CONFERENCE
Authors: NORDESTGAARD BG JAUHIAINEN M WIKLUND O FAGER G STENDER S DREVON CA OSE L
Citation: Bg. Nordestgaard et al., FIRST ANNUAL COPENHAGEN ATHEROSCLEROSIS CONFERENCE, Arteriosclerosis, thrombosis, and vascular biology, 15(10), 1995, pp. 1787-1790
BINDING OF PLATELET-DERIVED GROWTH-FACTOR AND LOW-DENSITY LIPOPROTEINS TO GLYCOSAMINOGLYCAN SPECIES PRODUCED BY HUMAN ARTERIAL SMOOTH-MUSCLE CELLS
Authors: FAGER G CAMEJO G OLSSON U OSTERGRENLUNDEN G LUSTIG F BONDJERS G
Citation: G. Fager et al., BINDING OF PLATELET-DERIVED GROWTH-FACTOR AND LOW-DENSITY LIPOPROTEINS TO GLYCOSAMINOGLYCAN SPECIES PRODUCED BY HUMAN ARTERIAL SMOOTH-MUSCLE CELLS, Journal of cellular physiology, 163(2), 1995, pp. 380-392
THROMBIN AND PROLIFERATION OF VASCULAR SMOOTH-MUSCLE CELLS
Authors: FAGER G
Citation: G. Fager, THROMBIN AND PROLIFERATION OF VASCULAR SMOOTH-MUSCLE CELLS, Circulation research, 77(4), 1995, pp. 645-650
MYOEPITHELIAL DIFFERENTIATION OF BASAL-CELL CARCINOMA AND METATYPIC SKIN-CANCER
Authors: BABAEV VR KHLEBNIKOVA AN KAZANTSEVA IA FAGER G
Citation: Vr. Babaev et al., MYOEPITHELIAL DIFFERENTIATION OF BASAL-CELL CARCINOMA AND METATYPIC SKIN-CANCER, Bulletin of experimental biology and medicine, 117(6), 1994, pp. 656-659
BINDING OF LOW-DENSITY LIPOPROTEINS BY PROTEOGLYCANS SYNTHESIZED BY PROLIFERATING AND QUIESCENT HUMAN ARTERIAL SMOOTH-MUSCLE CELLS
Authors: CAMEJO G FAGER G ROSENGREN B HURTCAMEJO E BONDJERS G
Citation: G. Camejo et al., BINDING OF LOW-DENSITY LIPOPROTEINS BY PROTEOGLYCANS SYNTHESIZED BY PROLIFERATING AND QUIESCENT HUMAN ARTERIAL SMOOTH-MUSCLE CELLS, The Journal of biological chemistry, 268(19), 1993, pp. 14131-14137
Risultati: 1-21 |